Table 2.
PDX models of triple-negative breast cancers
| PDX | Patient sourcea | Patient treatmentb | HER2 statusc | ER status | PR status | EGFR H-scored | BCL-2 H-scoree | BCL-XL H-score |
|---|---|---|---|---|---|---|---|---|
| HCI-001 | PT | + Prior T× | – | – | – | 188 | 10 | 100 |
| HCI-002 | PT | − Prior T× | – | – | – | 121 | 230 | 90 |
| HCI-004 | PT | − Prior T× | – | – | – | 76 | 10 | 220 |
| HCI-010 | PE | + Prior T× | – | – | – | 228 | 10 | 10 |
| HCI-015 | MT | + Prior T× | – | – | – | 193 | 20 | 60 |
| HCI-016 | PT | − Prior T× | – | – | – | 90 | 280 | 90 |
| HCI-019 | PT | − Prior T× | – | – | – | 208 | 40 | 155 |
aPT primary breast tumor, PE pleural effusion, MT metastatic breast tumor
bT×, treatment as previously described [16] and unpublished data kindly provided by A.W.
cHER2, ER, and PR as previously described [16] and unpublished data kindly provided by A.W.
dH-score represents the average of 4–6 tumors per PDX
eH-score represents one tumor surveyed per PDX kindly provided by A.W.